Heather Cios
Family · Glastonbury, CTNPI 1285330092
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Ardelyx, Inc. at 53.3% of the total. 2025 is the largest year on record at $11,202, 9.8 times the $1,140 reported in 2023. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 301 payments — averaging $49.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ardelyx, Inc.$8K
- Johnson & Johnson$2K
- AbbVie$848
- Takeda Pharmaceuticals U.S.A., Inc.$681
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$504
- Madrigal Pharmaceuticals$472
- plus $3K from 19 others
What the payments were for
- Consulting fees$1,74512%
- Speaking & faculty fees$3,70025%
- Travel & lodging$2,06014%
- Food & beverage$7,29249%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ardelyx, Inc. | 57 | $7,902 |
| Johnson & Johnson | 21 | $1,776 |
| AbbVie | 49 | $848 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $681 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $504 |
| Madrigal Pharmaceuticals | 12 | $472 |
| Ironwood Pharmaceuticals, Inc | 16 | $359 |
| Gilead | 7 | $281 |
| Phathom Pharmaceuticals, Inc. | 11 | $278 |
| Lilly USA, LLC | 13 | $273 |
| Pfizer | 16 | $208 |
| QOL Medical, LLC | 5 | $208 |
| Novo Nordisk | 5 | $184 |
| Braintree Laboratories, Inc. | 7 | $162 |
| Exact Sciences | 5 | $124 |
| Celltrion USA Inc. | 5 | $115 |
| E.r. Squibb & Sons, L.L.C. | 1 | $108 |
| Intercept Pharmaceuticals, Inc. | 3 | $62 |
| Sanofi | 2 | $53 |
| Nestle Healthcare Nutrition Inc. | 3 | $52 |
| Fresenius Kabi USA, LLC | 2 | $48 |
| Evoke Pharma, Inc. | 1 | $45 |
| Boehringer Ingelheim | 2 | $37 |
| Biocon Biologics Inc | 1 | $20 |
| Bristol Myers Squibb | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,816 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 56 | $175,217 |
| LinzessLinaclotide | 60 | $58,501 |
| XifaxanRifaximin | 19 | $44,115 |
| Mesalamine | 30 | $23,102 |
| ZenpepLipase/Protease/Amylase | 11 | $20,899 |
| MotegrityPrucalopride Succinate | 14 | $18,164 |
| Dexlansoprazole DrDexlansoprazole | 38 | $17,779 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 99 | $6,083 |
| Famotidine | 268 | $5,877 |
| Mesalamine ErMesalamine | 18 | $5,589 |
| Omeprazole | 296 | $5,279 |
| Rabeprazole Sodium | 18 | $5,061 |
| Pantoprazole Sodium | 416 | $4,981 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 27 | $4,414 |
| Sucralfate | 35 | $3,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $848 | $233,718116 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $504 | $44,11519 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $681 | $18,16414 claims |
| Braintree Laboratories, Inc.Sutab | $162 | $4,41427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Glastonbury
- Alina SchneiderGlastonbury$14K
- Debbie GouldGlastonbury$11K
- Sandra CriscuoloGlastonbury$11K
- Deborah HackettGlastonbury$9K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.